Table 2:

Baseline characteristics of older adults in Ontario who started, continued or resumed oral anticoagulant therapy after hospital discharge between September 2010 and March 2015

CharacteristicEntire cohort; no (%) of patients*Prevalent users; no (%) of patients*
Overall
n = 123 139
Incident users
n = 70 140
Prevalent users
n = 52 999
Standardized
difference
Switchers
n = 3674
Nonswitchers
n = 49 325
Standardized difference
Age, mean ± SD, yr78.2 ± 7.776.1 ± 7.181.1 ± 7.60.6979.4 ± 7.381.23 ± 7.60.24
Female sex68 408 (55.6)39 956 (57.0)28 452 (53.7)0.071846 (50.2)26 606 (53.9)0.07
Rural residence19 931 (16.2)11 892 (17.0)8039 (15.2)0.05580 (15.8)7459 (15.1)0.02
Anticoagulant dispensed
Apixaban5890 (4.8)2810 (4.0)3080 (5.8)0.08570 (15.5)2510 (5.1)0.35
Dabigatran6608 (5.4)2775 (4.0)3833 (7.2)0.14473 (12.9)3360 (6.8)0.20
Rivaroxaban51 409 (41.7)42 546 (60.7)8863 (16.7)1.011150 (31.3)7713 (15.6)0.38
Warfarin59 232 (48.1)22 009 (31.4)37 223 (70.2)0.841481 (40.3)35 742 (72.5)0.69
Indication
Atrial fibrillation within 10 yr62 957 (51.1)22 530 (32.1)40 427 (76.3)0.992988 (81.3)37 439 (75.9)0.13
Joint replacement within 35 d44 375 (36.0)38 939 (55.5)5436 (10.3)1.10502 (13.7)4934 (10.0)0.11
Major surgery during index hospital stay22 043 (17.9)17 384 (24.8)4659 (8.8)0.44590 (16.1)4069 (8.2)0.24
Active cancer within 180 d7858 (6.4)3548 (5.1)4310 (8.1)0.12278 (7.6)4032 (8.2)0.02
Deep vein thrombosis or pulmonary embolism during index hospital stay6407 (5.2)1783 (2.5)4624 (8.7)0.27349 (9.5)4275 (8.7)0.03
Prescribing physician specialty
Family medicine41 524 (33.7)12 604 (18.0)28 920 (54.6)0.821274 (34.7)27 646 (56.0)0.44
Orthopedic surgery31 394 (25.5)28 014 (39.9)3380 (6.4)0.87287 (7.8)3093 (6.3)0.06
Internal medicine9958 (8.1)5350 (7.6)4608 (8.7)0.04432 (11.8)4176 (8.5)0.11
Cardiology7083 (5.8)3840 (5.5)3243 (6.1)0.03441 (12.0)2802 (5.7)0.22
Hematology2324 (1.9)1808 (2.6)516 (1.0)0.12107 (2.9)409 (0.8)0.15
Other8792 (7.1)4843 (6.9)3949 (7.5)0.02387 (10.5)3562 (7.2)0.12
Unknown22 064 (17.9)13 681 (19.5)8383 (15.8)0.10746 (20.3)7637 (15.5)0.13
Past medical history
No. of hospital admissions within 1 yr, mean ± SD0.67 ± 1.160.30 ± 0.731.16 ± 1.420.760.99 ± 1.321.17 ± 1.430.13
No. of thromboembolic events within 3 yr13 741 (11.2)10 483 (19.8)3258 (4.6)0.48730 (19.9)9753 (19.8)0.00
Ischemic stroke4419 (3.6)990 (1.4)3429 (6.5)0.26228 (6.2)3201 (6.5)0.01
Transient ischemic attack2757 (2.2)853 (1.2)1904 (3.6)0.16142 (3.9)1762 (3.6)0.02
Peripheral vascular disease event2540 (2.1)680 (1.0)1860 (3.5)0.17106 (2.9)1754 (3.6)0.04
Systemic embolism705 (0.6)155 (0.2)550 (1.0)0.1034 (0.9)516 (1.0)0.01
Pulmonary embolism2393 (1.9)349 (0.5)2044 (3.9)0.23152 (4.1)1892 (3.8)0.02
Deep vein thrombosis3280 (2.7)580 (0.8)2700 (5.1)0.25204 (5.6)2496 (5.1)0.02
Hemorrhagic event within 3 yr13 406 (10.9)3627 (5.2)9779 (18.5)0.42616 (16.8)9163 (18.6)0.05
Intracranial bleeding777 (0.6)230 (0.3)547 (1.0)0.0927 (0.7)520 (1.1)0.03
Upper gastrointestinal bleeding3830 (3.1)1068 (1.5)2762 (5.2)0.21182 (5.0)2580 (5.2)0.01
Lower gastrointestinal bleeding1498 (1.2)453 (0.6)1045 (2.0)0.1285 (2.3)960 (1.9)0.03
Other major bleed8750 (7.1)2132 (3.0)6618 (12.5)0.36392 (10.7)6226 (12.6)0.06
Comorbidities
Congestive heart failure47 133 (38.3)14 265 (20.3)32 868 (62.0)0.932096 (57.0)30 772 (62.4)0.11
Hypertension106 292 (86.3)57 447 (81.9)48 845 (92.2)0.313378 (91.9)45 467 (92.2)0.01
Diabetes46 522 (37.8)22 569 (32.2)23 953 (45.2)0.271627 (44.3)22 326 (45.3)0.02
Renal dysfunction§11 216 (9.1)2491 (3.6)8725 (16.5)0.44418 (11.4)8307 (16.8)0.16
Liver dysfunction1349 (1.1)343 (0.5)1006 (1.9)0.1368 (1.9)938 (1.9)0.00
Drug use disorder14 226 (11.6)11 642 (16.6)2584 (4.9)0.39202 (5.5)2382 (4.8)0.03
Alcohol use disorder in previous 3 yr1401 (1.1)517 (0.7)884 (1.7)0.0964 (1.7)820 (1.7)0.01
Charlson Comorbidity Index score
 020 946 (17.0)11 714 (16.7)9232 (17.4)0.02669 (18.2)8563 (17.4)0.02
 114 766 (12.0)6041 (8.6)8725 (16.5)0.24637 (17.3)8088 (16.4)0.03
 ≥ 232 563 (26.4)8967 (12.8)23 596 (44.5)0.751355 (36.9)22 241 (45.1)0.17
 NA (no hospital admission)54 864 (44.6)43 418 (61.9)11 446 (21.6)0.901013 (27.6)10 433 (21.2)0.15
CHA2DS2-VASc score
 Mean ± SD4.08 ± 1.593.49 ± 1.374.86 ± 1.530.954.77 ± 1.474.87 ± 1.530.07
 Median (IQR)4 (3–5)3 (3–4)5 (4–6)0.985 (4–6)5 (4–6)0.07
HAS-B_ED score
 Mean ± SD2.20 ± 0.682.09 ± 0.632.36 ± 0.710.412.30 ± 0.692.37 ± 0.720.09
 Median (IQR)2 (2–3)2 (2–2)2 (2–3)0.382 (2–3)2 (2–3)0.10
Concomitant medication within previous 120 d
Nonsteroidal anti-inflammatory drug19 273 (15.7)15 344 (21.9)3929 (7.4)0.42304 (8.3)3625 (7.3)0.03
Acetylsalicylic acid2870 (2.3)2212 (3.2)658 (1.2)0.1341 (1.1)617 (1.3)0.01
Other antiplatelet7026 (5.7)4459 (6.4)2567 (4.8)0.07207 (5.6)2360 (4.8)0.04
Amiodarone4048 (3.3)598 (0.9)3450 (6.5)0.30242 (6.6)3208 (6.5)0.00
Selective serotonin reuptake inhibitor14 864 (12.1)6189 (8.8)8675 (16.4)0.23428 (11.6)8247 (16.7)0.15
Antibiotic**17 345 (14.1)7384 (10.5)9961 (18.8)0.24541 (14.7)9420 (19.1)0.12
  • Note: IQR = interquartile range, NA = not available, SD = standard deviation.

  • * Except where noted otherwise.

  • Data missing for less than 0.07% of patients.

  • Patients could have more than 1 indication.

  • § Included International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) codes for dialysis, chronic renal disease, renal cancer and renal surgery.

  • Included ICD-10 codes for cirrhosis, chronic liver disease, liver cancer, hepatitis and liver surgery.

  • ** Within 30 days.